• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • AIDS
    42 Drugs classified under this therapeutic system

    All the Therapeutic System Drugs

    Filter by letter: ALL A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    Abacavir Lamivudine Taro
    Taro International Ltd
    not in the basket chart
    Multiple ingredients
    Abacavir Lamivudine Taro

    : Nucleoside & Guanosine Reverse Transcriptase Inhibitor. Lamivudine 300 mg, Abacavir 600 mg.
    TABS.:30. The recomm. dosage for adult.& child. over the age of 12 wt. at least 40 kg, is one tab., once dly. See lit.
    Indicated in antiretrovir. comb. ther. for the tmt. of (HIV) infect. in adult., adolesc. and child. weigh. at least 25 kg.
    C/I: Hypersens.


    partial basket chart
    Multiple ingredients

    Antivirals for Treatment of HIV Infections. Efavirenz 600 mg, Emtricitabine 200 mg, Tenofovir Disoproxil 245 mg.
    F.C. TABS.: 30. Adults: 1 tab dly on empty stmch. Under 18 yrs: Not recommend. Eldery: use with caution. Not recommend. in pts. with CLcr<50 ml/min. See lit.
    For use alone as a complete regimen or in
    comb. with other antiretroviral agents for
    the tmt of HIV-1 infect. in adults.
    C/I: Hypersens. to the product; Sev. hep.
    impair. (CPT, Class C); Co-admin. with
    terfenadine, astemizole, cisapride,
    midazolam, triazolam, pimozide,
    bepridil, or ergot alkaloids (for ex.
    ergotamine, dihydroergotamine,
    ergonovine, methylergonovine).
    Co-admin. with voriconazole. Co-admin.
    with herbal prep. cont. St. John’s wort
    (Hypericum perforatum).

    Axiban Sublingual Drops IMC-Medical Grade Cannabis Oil
    not in the basket chart
    Multiple ingredients
    Axiban Sublingual Drops IMC-Medical Grade Cannabis Oil

    Cannabinoids. THC 0.3, 0.9, 1.5, 3, 4.5, 6 mg/drop, CBD 0.6, 0.9, 1.2, 3, 4.5, 6 mg/drop.
    *This product requires a license for medical cannabis.
    BOTTLE. (sublingual drop.): 10gr (330 drops). Dosage should be adjust. individual.
    The Israel MOH has outlined in Guidance 106 the 12 indicat. for which med. cannabis is indicated. Accord. to this guidance, the 11 indicat. for this product are:
    Chemother-induc. nausea and vomit. (CINV)/ chemother induc. pain.
    Metastat. cancer pain.
    Neuropath. pain.
    Spastic. of MS.
    Pain in Parkinson's dis.
    Cachexia in AIDS.
    Tourette's syndr.
    Recalcitrant epilep. in adult. (Note: Accord. to Guidance 106, med. cannab. is also indic. for recalcitrant epilep. in ped. pts. but this is not an indicat. for this product)
    Palliative care for termin. ill pts.
    Post- traum. stress disord.
    In general, the use of med. cannabis is indicated in pts. who have adequate. tried and failed convent. ther.
    Please refer to Guidance 106 for details.
    In addition, for an individ. pt. with a clinical. signific. med. condit. that cannot be adequate. managed by convent. ther. and which is not includ. as one of the 12 approved indicat. (eg autism, fibromyalgia), the physician can appeal to the MOH Committee for Med. Cannabis to ask for approval on an individ. exception. basis.
    C/I: Prior, current/ family history (1st degr. relative) of psychos. or schizophr. or schizoaffective disord., a hist. of addict. or substance abuse (include. cannabis use disord.or addict. to alcohol), use in preg.or lact., use in pts. <18 yrs. old, bipol.disord., hypersens. to cannabis, coconut oil, palm kernel oil.
    In pts. with hepat. cancer, it is recommend. not to use med. cannab. that contains THC.
    See lit.

    partial basket chart
    Multiple ingredients

    Antiretrovirals. Bictegravir 50 mg, Emtricitabine 200 mg, Tenofovir Alafenamide 25 mg.
    F.C. TABS.: 30. 1 tab×1/d with/without
    food. If the patient misses a dose
    within 18 hours of the time it is
    usually taken, the patient should take
    the drug as soon as possible and
    resume the normal dosing schedule.
    If a patient misses a dose by more
    than 18 hours, the patient should not
    take the missed dose and simply
    resume the usual dosing schedule.
    If the patient vomits within 1 hour of
    taking the drug another tablet should
    be taken. If a patient vomits more
    than 1 hour after taking the drug they
    do not need to take another dose of
    the drug until the next regularly
    scheduled dose.
    Treatment of adults infected with human
    immunodeficiency virus-1 (HIV-1) without
    present or past evidence of viral resistance
    to the integrase inhibitor class,
    emtricitabine or tenofovir.
    C/I: Hypersens.
    Co-admin. with rifampicin and St John’s
    wort (Hypericum perforatum).

    partial basket chart

    Chemokine Receptor Antagonist. Maraviroc 150 mg, 300 mg.
    F.C. TABS: 10, 30, 60, 90, 180 x 150 mg,
    300 mg. Depend. on interacts. With
    co-admin. antiretrovir. ther. and other
    medicin. prods. See lit.
    In comb. with other antiretrovir. medicin.
    prods., for the tmt. experienced adult pts.
    infect. with only CCR5-tropic HIV-
    1 detectable.
    C/I: Hypersens. to active substance or to
    peanut, soya or any excips., pts with
    severe renal impair. or ESRD (CrCl <30
    ml/ min) who take potent CYP3A4 inh.
    or inducers.

    partial basket chart

    DNA Polymerase Inhibitor. Ganciclovir 500 mg.
    VIALS: 1, 5. Adults: Initially 5mg/kg
    every 12 hrs. (at a constant rate of 1
    hr.), every 12 hrs. by I.V. inf. for 14 - 21
    days. Maint: 6mg/kg dly. by I.V. infus. 5
    days/wk. or 5 mg/kg dly. for 7 days/wk.
    Only in the tmt. of CMV retinit. in
    immunocompromised pts., prevent. CMV
    dis. in transplant pts. at risk for CMV dis.

    Other therapeutic systems under Infections